Selection of blockbuster announcements

1、$China Telecom Corporation (00728.HK) $Net profit in the first quarter was 7.223 billion yuan, an increase of 12.14% over the same period last year

China Telecom Corporation disclosed the first quarter report that during the reporting period, the company achieved operating income of 118.576 billion yuan, an increase of 11.53% over the same period last year, net profit of 7.223 billion yuan, an increase of 12.14% over the same period last year, and basic earnings per share of 0.08 yuan.

2、Poly Xiexin Energy (03800.HK) $The net profit in the first quarter is expected to reach 3.03 billion yuan, benefiting from the improvement of photovoltaic materials business.

Poly Xiexin Energy (3800.HK) issued a positive profit forecast. It is expected that the company's unaudited profit attributable to shareholders in the first quarter of this year will be 3.03 billion yuan, compared with about 6.99 billion yuan in the last quarter. Xiexin Technology said that the significant increase in profit attributable to shareholders during the period was mainly due to the improvement in the business performance of photovoltaic materials. The revenue of the photovoltaic materials division in the first quarter of this year was about 6.68 billion yuan, and the comprehensive gross profit margin of the division during the period was about 46%. The gross profit margin of granular silicon products continued to be higher than that of bar silicon by more than 15 percentage points.

3、$Kellein (06821.HK) $Net profit in the first quarter was 499 million yuan, an increase of 223.59% over the same period last year

Kelleying disclosed the first quarter report, during the reporting period, the company achieved operating income of 2.062 billion yuan, an increase of 165.28% over the same period last year; net profit of 499 million yuan, an increase of 223.59% over the same period last year; and basic earnings per share of 1.91 yuan. During the reporting period, the company's revenue grew strongly, the "two-wheel drive" strategy was effectively promoted, the small molecule business grew by 165.9% year-on-year, the emerging business grew by 157.4%, and the revenue growth of chemical macromolecules, biological macromolecules, preparations and clinical CRO all exceeded 100%.

4、$Shanghai Fosun Pharmaceutical (02196.HK) $Subsidiary drugs are approved in clinical trials

Shanghai Fosun Pharmaceutical announced that Fuhong Hanlin received approval from the State Drug Administration to conduct clinical trials of its independently developed Hans-like ®(Srelli monoclonal antibody injection) combined with recombinant anti-EGFR humanized monoclonal antibody injection and Hanbetai ®(bevacizumab injection) for first-line treatment of unresectable or metastatic hepatocellular carcinoma.

5、$CSPC Pharmaceutical (01093.HK) $Anti-tumor nano-drugs approved in clinical trials

CSPC Pharmaceutical announced that the "Cisplatin Micellar injection" developed by CSPC Pharmaceutical Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. has been approved by the State Drug Administration to carry out clinical trials in China. The approved clinical indication is advanced malignant solid tumor. based on the results of preclinical research, this product is expected to show good results in clinical trials. This product belongs to the category 2 registered in China. At present, there are no similar products on the market in the world. The group means that the product will be put on the market as soon as possible.

Important matters

Gome Retail (00493): proposed "10 in 1" share merger

CNOOC Limited (00883) has completed the RMB share issue.

China Antibody-B (03681): SN1011 New Drug Research Application approved by SDA

Sino Biopharmaceutical (01177): new antineoplastic class I drug "TQB2930" approved clinical trial

CSPC Pharmaceutical (01093): anti-tumor nano-drug "cisplatin micellar injection" approved in clinical trial

Drug Mingju Nuo-B (02126): application for clinical trial of Ruiji Orenser injection in children and young adults approved

Eber Technology (02708) won the bid for Shaanxi Mobile 2022-2023 5G frequency shift MIMO system centralized procurement project with 15.594 million yuan.

Clover organism-B (02197): inoculation of SCB-2019 (CpG 1018 ╱ aluminum adjuvant) in previously infected people can provide more significant protective effect on COVID-19.

Saisheng Pharmaceutical (06600): the State Drug Administration accepts DANYELZA ®and GM-CSF combined with irinotecan and temozolomide for IND in patients with primary refractory or first recurrent high-risk neuroblastoma.

Fuhong Hanlin (02696): phase 2 clinical trial of Serurimab injection combined with HLX07 and bevacizumab injection in the first-line treatment of unresectable or metastatic hepatocellular carcinoma was approved by the State Drug Administration.

Financial report data

Poly Xiexin Energy (03800) is expected to make a net profit of 3.03 billion yuan in the first quarter, benefiting from the improvement of photovoltaic materials business.

Fosun Tourism Culture (01992) in the first quarter, the turnover of resorts and tourism destination operations and tourism and leisure services and solutions reached 4.198 billion yuan, an increase of about 306.6% over the same period last year.

Kelleying (06821) released its first-quarter results, with a net profit of 499 million yuan, an increase of 223.59% over the same period last year.

Skyworth Group (00751) released Skyworth Digital (000810.SZ) first quarter net profit of about 208 million yuan, an increase of 33.74% over the same period last year.

China Telecom Corporation (00728) released that the profit attributable to shareholders in the first quarter was 7.223 billion yuan, up 12.1% from the same period last year.

Sinopharm Group (01099): the operating profit of Chinese medicine equipment in the first quarter was 513 million yuan, an increase of 2.28% over the same period last year.

Total copper output of Minmetals Resources (01208) in the first quarter was about 79100 tons, an increase of 2% over the same period last year.

Kaisa Health (00876) announces profit attributable to shareholders in 2021 of HK $2.359 million year-on-year turnround

Yanzhou Mining Energy (01171) first quarter commercial coal sales of 25.58 million tons fell 2.75% compared with the same period last year.

Raw coal production in Australia (03668) was 13.3 million tons in the first quarter, down 21% from the previous quarter.

Minmetals Real Estate (00230) first quarter contract sales of 3.07 billion yuan fell 30.7% compared with the same period last year.

China Merchants Land (00978) released first-quarter operating data total contract sales of about 7.724 billion yuan decreased by 45.6% compared with the same period last year.

Repurchase cancellation

HSBC Holdings PLC (00005) spent 41.0603 million pounds to buy back 7.8129 million shares on April 19th.

Standard Chartered PLC (02888) spent about 8.3835 million pounds to buy back 1.6414 million shares on April 19th

China Software International (00354) spent HK $12.7655 million to buy back 2 million shares on April 20.

JD Health (06618) HK $12.64 million buyback 265000 shares on April 20

China Conch Venture (00586) spent HK $8.566 million to buy back 397500 shares on April 20.

Baoye Group (02355) spent about HK $6.6076 million to buy back 1.55 million shares on April 20.

Ping An Healthcare And Technology (01833) HK $5.444 million buyback 260000 shares on April 20

Additional placement

Techtronic Industries (00669) issued 20, 000 additional shares as a result of the exercise of share options

Man Wah (01999) was issued 514000 shares due to the exercise of share options

China Xinlianxin Chemical Fertilizer (01866) plans to place 56.5 million shares first and then new, with a maximum net raise of HK $359 million.

Pharmaron Beijing Co., Ltd.* (03759) proposes to grant special authorizations related to convertible bonds to issue additional H shares.